Delivery Order SPE2DB22D3016-SPE2DB26FAAH7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,265.45 on October 15, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30. This non-competitive delivery order is a firm fixed price contract with a completion date of October 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $2,511.19 delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of October 22, 2025, and carries no set-aside designation, indicating it was competitively awarded. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Vemlidy 25 mg tablets (30-count units) at a ceiling value of $3,346.62. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for ultimate completion by October 21, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order valued at $5,080.98 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on August 27, 2025, with completion scheduled for August 28, 2025. This non-set-aside, firm fixed-price delivery order represents a pharmaceutical procurement supporting federal medical supply needs. The award was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Vemlidy 25 mg tablets in a quantity of 30 units, with a ceiling value of $11,313.60. This firm fixed-price delivery order is scheduled for completion by September 23, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, leveraging AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,847.30 by the Defense Logistics Agency on October 23, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). The award is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 24, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,873.72 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-unit package) on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime contract...
- The Defense Logistics Agency awarded a $7,245.84 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 2, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $24,593.10 on September 24, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 25, 2025. The contract is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value...
- The Defense Logistics Agency awarded a $8,731.21 delivery order to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on October 24, 2025, with completion expected by October 27, 2025. This competitively awarded, non-set-aside contract reflects a firm fixed price arrangement typical of pharmaceutical supply transactions under the DLA's medical procurement framework. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAH7Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,740.85 on October 21, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This is a firm fixed-price contract with no set-aside designation, competitively awarded under the Defense Logistics Agency's Medical Supply Chain. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of October 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, providing brand-name and generic medications, vaccines, and medical supplies to military and veteran healthcare systems. As a major healthcare solutions provider headquartered in Pennsylvania and registered in SAM.gov, the company holds extensive experience fulfilling federal pharmaceutical requirements across multiple therapeutic domains through competitive delivery orders with firm fixed pricing. This award reflects the company's ongoing support of the Defense Health Agency and broader federal healthcare programs through its comprehensive pharmaceutical supply capabilities under the DLA's global prime vendor contract structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 10/21/25 |